American Portfolios Advisors’s Marker Therapeutics MRKR Stock Holding History

American Portfolios Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7.81K	Hold	2,117	–	–	﹤0.01%	2630
2022 Q2	$6.99K	Hold	2,117	–	–	﹤0.01%	2700
2022 Q1	$9.31K	Hold	2,117	–	–	﹤0.01%	2715
2021 Q4	$20.1K	Buy	2,117 +200	+10%	+$2.66K	﹤0.01%	2328
2021 Q3	$32.4K	Buy	1,917 +1,050	+121%	+$21.5K	﹤0.01%	2015
2021 Q2	$24.2K	Hold	867	–	–	﹤0.01%	2133
2021 Q1	$19.4K	Buy	867 +150	+21%	+$3.43K	﹤0.01%	2090
2020 Q4	$10.4K	Buy	717 +430	+150%	+$6.68K	﹤0.01%	2094
2020 Q3	$4.3K	Sell	287 -50	-15%	-$912	﹤0.01%	2346
2020 Q2	$6.98K	Buy	337 +20	+6%	+$437	﹤0.01%	2088
2020 Q1	$6.02K	Hold	317	–	–	﹤0.01%	2022
2019 Q4	$9.13K	Sell	317 -70	-18%	-$2.55K	﹤0.01%	2038
2019 Q3	$19.8K	Sell	387 -40	-9%	-$2.36K	﹤0.01%	1667
2019 Q2	$33.8K	Buy	427 +182	+74%	+$10.8K	﹤0.01%	1440
2019 Q1	$16.2K	Buy	+245	New	+$14.3K	﹤0.01%	1653

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Portfolios Advisors's MRKR Position: Q3 2022 in Review

American Portfolios Advisors held its Marker Therapeutics (MRKR) position steady in Q3 2022 at 2,117 shares worth $7.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

American Portfolios Advisors first reported a position in MRKR in Q1 2019 and has held it in 15 quarters since. The position peaked at $33.8K in Q2 2019. 45 funds tracked by Wall St. Rank hold MRKR as of Q3 2022.

American Portfolios Advisors held 2,117 shares of Marker Therapeutics worth $7.81K as of Q3 2022.
American Portfolios Advisors left its Marker Therapeutics share count unchanged in Q3 2022.
Marker Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2630 holding.
American Portfolios Advisors first reported a position in Marker Therapeutics in Q1 2019 and has held it in 15 quarters since.
American Portfolios Advisors's Marker Therapeutics position peaked at $33.8K in Q2 2019.
45 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.